Donor Stem Cell Transplant for High-Risk Sickle Cell and Related Blood Disorders
Tests a donor stem cell transplant in people with sickle cell disease.
Key facts
- Who runs it
- Masonic Cancer Center, University of Minnesota
- Where
- Minneapolis, United StatesSee the site
- Trial code
- Registry title
- Allo HSCT for High Risk Hemoglobinopathies
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 62 people, planned
- Started
- 19 Nov 2024
- Expected to end
- 1 Jun 2032
- Type of study
- Interventional, 5 groups
- Treatments tested
- Alemtuzumab
- Total Body Irradiation
- Cell Infusion
- Thymoglobulin
- Fludarabine
- Busulfan
- Cyclophosphamide
- Sirolimus
- Tacrolimus
- Mycophenolate Mofetil
- Plerixafor (mozobil)
- Record updated
- 4 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people with sickle cell disease, transfusion-dependent thalassemia, Diamond Blackfan Anemia or other non-cancer blood disorders who can have a donor stem cell transplant.
- Age
- Up to 55 years
- Sex
- All
- Disease stage
- Sickle cell disease (with a fully matched sibling donor, whatever the frequency or severity of symptoms), transfusion-dependent alpha- or beta-thalassemia, Diamond Blackfan Anemia, or other non-malignant blood disorders.
Main reasons for not taking part
- Pregnant, breastfeeding or planning pregnancy during the study
- HIV infection with a detectable viral load
- Active, uncontrolled infection
- Known allergy to any study component
- Psychiatric illness or social situation that would limit following the study requirements
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Sickle Cell Disease (SCD)
- SCD Patients with a fully matched sibling donor (MSD) irrespective of the frequency or severity of symptoms MSD transplant can be considered. Parents/patient must be counseled as to the risks and benefits and provide their voluntary informed consent
- Transfusion Dependent Alpha- or Beta- Thalassemia
- Diamond Blackfan Anemia
- Other Non-Malignant Hematologic Disorders
- Karnofsky ≥ 60%, Lansky play score ≥ 60. Patients with lower performance score can be considered based on study team's evaluation
- Sexually active persons of childbearing potential or persons with partners of childbearing potential must agree to use a highly effective form of contraception during study treatment and for at least 4 months after the transplant
Who cannot take part
- HIV infection with a detectable viral load. All HIV+ patients must be evaluated by infectious disease (ID) and an HIV management plan established prior to transplantation
- Active, uncontrolled infection - infection that is stable or improving after 1 week of appropriate therapy (4 weeks for presumed or documented fungal infections) will be permitted
- Known allergy to any of the study components
- Psychiatric illness/social situations that, in the judgement of the enrolling Investigator, would limit compliance with study requirements
- Other illness or a medical issue that, in the judgement of the enrolling Investigator, would exclude the patient from participating in this study
- Pregnant, breastfeeding or intending to become pregnant during the study. Persons of childbearing potential must have a negative pregnancy test (serum or urine) within 30 days of the start of treatment
Where in United States
- Masonic Cancer CenterMinneapolis, United StatesContact: Ashish Gupta, MBBS, MPHTaking people
About the trial
What the trial wants to find out
A single center, open label, interventional, phase II trial for donor transplant for high risk hemoglobinopathies and other red cell transfusion dependent disorders utilizing allogeneic hematopoietic stem cell transplantation (HSCT) regimens.
The 5 groups in the trial
- Arm A - ClosedTreatment being tested
Arm A Matched sib regimen - Age 6 -55 (per physician preference for patients over 6) Campath/TBI
Treatment: Alemtuzumab, Total Body Irradiation, Cell Infusion, Sirolimus, and Mycophenolate Mofetil
- Arm BTreatment being tested
Arm B Matched sib regimen - 0-55 (per physician preference for patients over 6) ATG/Flu/Bu
Treatment: Cell Infusion, Thymoglobulin, Fludarabine, Busulfan, Tacrolimus, and Mycophenolate Mofetil
- Arm CTreatment being tested
Arm C Fully Matched unrelated donor (MUD)- - 0-55 years; ATG/Flu/Bu
Treatment: Cell Infusion, Thymoglobulin, Fludarabine, Busulfan, Tacrolimus, Mycophenolate Mofetil, and Plerixafor (mozobil)
- Arm DTreatment being tested
Arm D: Haploindentical or mismatched unrelated donors (MMUD) - 0-55 years; ATG/Thiotepa/Cyclophosphamide/MESNA/Flu/TBI
Treatment: Sirolimus, Tacrolimus, and Plerixafor (mozobil)
- Arm ETreatment being tested
Matched sib regimen - Age 6-55 (per physician preference for patients over 6) Campath/TBI with peripheral blood stem cell graft
Treatment: Total Body Irradiation, Cell Infusion, Thymoglobulin, Fludarabine, Cyclophosphamide, Sirolimus, Tacrolimus, and Mycophenolate Mofetil
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Allogeneic Hematopoietic Stem Cell Transplant for Patients With High Risk Hemoglobinopathies and Other Red Cell Transfusion Dependent Disorders
- Plain-language title
- Donor Stem Cell Transplant for High-Risk Sickle Cell and Related Blood DisordersGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 4 June 2026